Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 3491053)

Published in Health Qual Life Outcomes on August 23, 2012

Authors

Khaled Al-shair1, Hana Muellerova, Janelle Yorke, Stephen I Rennard, Emiel F M Wouters, Nicola A Hanania, Amir Sharafkhaneh, Jørgen Vestbo, ECLIPSE investigators

Author Affiliations

1: University of Manchester, Medicines Evaluation Unit, NIHR Translational Research Facility, Manchester Academic Health Sciences Centre, University Hospital of South Manchester Foundation Trust, Wythenshawe, Manchester, UK. alshair02@yahoo.com

Associated clinical trials:

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE) | NCT00292552

Feasibility, of Tele-rehabilitation Following COVID-19 | NCT04511962

Articles cited by this

ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79

A measure of quality of life for clinical trials in chronic lung disease. Thorax (1987) 10.87

The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res (1995) 9.99

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax (1999) 8.63

Development and first validation of the COPD Assessment Test. Eur Respir J (2009) 8.06

Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage (1997) 5.98

Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17

Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J (2008) 4.53

An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol (2007) 4.10

Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis (1994) 3.59

Fatigue in cancer patients compared with fatigue in the general United States population. Cancer (2002) 3.34

Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest (2007) 2.67

Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J (2011) 2.38

Validation and comparison of reference equations for the 6-min walk distance test. Eur Respir J (2007) 2.04

Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med (2008) 1.68

Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage (2007) 1.62

Fatigue: a concept analysis. Int J Nurs Stud (1996) 1.47

An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol (2003) 1.34

Subjective fatigue, influencing variables, and consequences in chronic obstructive pulmonary disease. Nurs Res (2006) 1.32

Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2010) 1.24

Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14

Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 1.07

Fatigue in patients with chronic obstructive pulmonary disease. J Adv Nurs (2004) 1.07

The influence of decisions made by developers on health status questionnaire content. Qual Life Res (1998) 1.05

Internal construct validity of the Oxford Knee Scale: evidence from Rasch measurement. Arthritis Rheum (2007) 1.02

Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. Respir Res (2011) 0.95

Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. Thorax (2009) 0.91

Fatigue in COPD: prevalence and effect on outcomes in pulmonary rehabilitation. Chron Respir Dis (2011) 0.82

Articles by these authors

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86

Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA (2006) 10.54

Lebrikizumab treatment in adults with asthma. N Engl J Med (2011) 8.07

A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93

Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med (2011) 6.56

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17

Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69

Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity (2007) 5.36

Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17

Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J (2008) 4.53

An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49

Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19

Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16

A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med (2012) 4.10

GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet (2009) 3.93

Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70

C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.69

Systemic effects of smoking. Chest (2007) 3.63

Risk indexes for exacerbations and hospitalizations due to COPD. Chest (2007) 3.55

Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 3.54

Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44

What is chronic obstructive pulmonary disease anyway?: Continua, categories, cut points, and moving beyond spirometry. Am J Respir Crit Care Med (2013) 3.39

Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30

Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med (2012) 3.00

Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest (2005) 2.98

Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest (2003) 2.90

FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87

Reversible cigarette smoke extract-induced DNA damage in human lung fibroblasts. Am J Respir Cell Mol Biol (2004) 2.82

Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med (2010) 2.80

Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA (2013) 2.59

'Highlights from this issue’ in the November issue of Thorax. Thorax (2013) 2.59

Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52

Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc Natl Acad Sci U S A (2006) 2.51

Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest (2008) 2.37

Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest (2015) 2.32

Disturbed intestinal integrity in patients with COPD: effects of activities of daily living. Chest (2014) 2.27

Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet (2012) 2.24

Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.21

Differences in content and organisational aspects of pulmonary rehabilitation programmes. Eur Respir J (2013) 2.20

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20

Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci U S A (2004) 2.19

Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol (2002) 2.16

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 2.13

Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest (2004) 2.08

A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD (2012) 2.07

Exercise capacity before and after an 8-week multidisciplinary inpatient rehabilitation program in lung cancer patients: a pilot study. Lung Cancer (2006) 2.07

Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. Eur Respir J (2013) 2.05

Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med (2007) 2.04

Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99

A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98

Inaccuracy of estimating peak work rate from six-minute walk distance in patients with COPD. COPD (2012) 1.98

Effects of neuromuscular electrical stimulation of muscles of ambulation in patients with chronic heart failure or COPD: a systematic review of the English-language literature. Chest (2009) 1.81

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.79

Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 1.79

A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest (2007) 1.79

Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.76

Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res (2006) 1.75

Cells derived from the circulation contribute to the repair of lung injury. Am J Respir Crit Care Med (2004) 1.74

Airway mucus: From production to secretion. Am J Respir Cell Mol Biol (2006) 1.73

Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.72

Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72

Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc (2015) 1.72

Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol (2002) 1.71

Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med (2009) 1.70

Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med (2005) 1.67

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs (2008) 1.67

Gender differences of airway dimensions in anatomically matched sites on CT in smokers. COPD (2011) 1.66

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J (2013) 1.66

Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. Am J Respir Crit Care Med (2010) 1.66

Racial differences in quality of life in patients with COPD. Chest (2011) 1.64

Predictors of objective cough frequency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.64

An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63

[Prevalence of chronic obstructive pulmonary disease in Copenhagen. Results from The Copenhagen City Heart Study]. Ugeskr Laeger (2007) 1.62

Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics (2006) 1.61

Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition (2003) 1.60

Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med (2005) 1.60

COPD: the dangerous underestimate of 15%. Lancet (2006) 1.60

Efficacy of tiotropium inhalation powder in african-american patients with chronic obstructive pulmonary disease. COPD (2008) 1.59

Risk factors for osteoporosis in Caucasian patients with moderate chronic obstructive pulmonary disease: a case control study. Bone (2012) 1.56

Leptin as regulator of pulmonary immune responses: involvement in respiratory diseases. Pulm Pharmacol Ther (2013) 1.54

Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med (2005) 1.54